Evidence map›Paper›PMID 32130964›Full record

ReviewSeminars in nephrology2020

The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.

Jennifer J Huang, James J Hsieh

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Therapeutic Strategies for Angiogenesis Based on Endothelial Cell Epigenetics.Journal of cardiovascular translational research · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jennifer J HuangMolecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO.
James J HsiehMolecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO. Electronic address: jhsieh@wustl.edu.
Molecular Oncology (United States) · US

Funding

WASHINGTON UNIVERSITY HUMAN TUMOR ATLAS RESEARCH CENTERU2CCA233303 · NCI · WASHINGTON UNIVERSITY · PI DING, LI · 2018 to 2023
$9.7M
Genetic Loss-of-Function Studies of SETD2 in Kidney TumorigenesisR01CA223231 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHENG, EMILY H · 2018 to 2022
$2.7M
NCI NIH HHS R01 CA223231NCI NIH HHS U2C CA233303
6 · The paper itself

Abstract

Oncologic treatments for renal cell carcinoma (RCC) have undergone a major revolution in the past 2 decades, moving away from the pre-2004 Dark Age during which interleukin 2 and interferon-α were the only therapeutic options and induced treatment responses in only 5% to 10% of patients with metastatic disease. The development of anti-angiogenic tyrosine kinase inhibitors against vascular endothelial growth factor receptor 2 and inhibitors of mammalian target of rapamycin complex 1 in 2005 introduced the Modern Age with better overall and progression-free survival and a greater number of patients (30%-40%) responding to and (∼80%) benefiting from these targeted therapeutic agents. The coming of age of the immuno-oncology era with the use of immune checkpoint inhibitors (ICIs) have ushered us into the Golden Age of metastatic RCC care, in which combined administrations of two ICIs (anti-programmed cell death protein 1/programmed death-ligand 1 and anti-cytotoxic T-lymphocyte-associated protein 4 or one tyrosine kinase inhibitor plus one ICI (anti-programmed cell death protein 1/programmed death-ligand 1) have recast the treatment landscape of clear cell RCC, the most common RCC subtype, with an approximately 60% response rate and an approximately 90% disease control rate that further improves metastatic RCC survival. Exciting clinical trials are in the pipeline investigating complementary/synergistic molecular mechanisms, based on studies investigating the biology, pathology, and genomics of renal carcinoma and the respective treatment outcome. This will enable us to enter the Diamond Age of precision medicine in which a specific treatment can be tailored to the specific biological and pathologic circumstance of an individual kidney tumor to offer more effective yet less toxic therapy.

Indexed as

Angiogenesis InhibitorsAntineoplastic AgentsAntineoplastic Agents, ImmunologicalCarcinoma, Renal CellHumansImmune Checkpoint InhibitorsInterferon alpha-2Interleukin-2Kidney NeoplasmsMechanistic Target of Rapamycin Complex 1Protein Kinase InhibitorsTreatment OutcomeVascular Endothelial Growth Factor Receptor-2Angiogenesis InhibitorsAntineoplastic AgentsAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsInterferon alpha-2Interleukin-2Mechanistic Target of Rapamycin Complex 1Protein Kinase InhibitorsVascular Endothelial Growth Factor Receptor-2combination therapyimmunotherapyRenal cell carcinomatargeted therapy

Identifiers

PMID32130964
PMCPMC8858035
OpenAlexW3008405960

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.